A carregar...
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
OBJECTIVE: The phase III POLO trial demonstrated that olaparib as maintenance therapy for metastatic pancreatic cancer patients with a germline BRCA mutation had greater efficacy than placebo, but maintenance olaparib places an economic burden on patients. This study evaluated the cost-effectiveness...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751318/ https://ncbi.nlm.nih.gov/pubmed/33364840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S283169 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|